Gene-Editing Therapeutics Market Growth, Demand and Production Forecast 2035
According to market projection, the gene-editing therapeutics market is entering a rapid expansion phase, rising from USD 2.47 billion in 2026 to USD 18.15 billion by 2035 at a 24.80% CAGR. Research identifies CRISPR/Cas, ex-vivo edited cell therapies, and genetic and rare disease applications as the market's leading segments, while base/prime editing, in-vivo therapeutics, cardiovascular applications, and LNP-based delivery systems are gaining momentum. North America maintains market leadership, Asia Pacific records the fastest growth, and innovation from companies including CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, and Verve Therapeutics continues to shape the competitive landscape.
Last Updated : 20 July 2026
Category: Therapeutic Area
Insight Code: 6079
Format: PDF / PPT / Excel